Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-κB, CCR1, chemokine CCL5/RANTES and interleukin-1β in PBMC allergic and non-allergic patients

• Published in: Immunobiology (1979) 2017-03, Vol.222 (3), p.571-581
• Main Authors: Kordulewska, Natalia Karolina, Kostyra, Elżbieta, Cieślińska, Anna, Matysiewicz, Michał, Fiedorowicz, Ewa, Sienkiewicz-Szłapka, Edyta
• Format: Article
• Language: English
• Subjects: Advanced Basic Science; Allergic disease; Allergy and Immunology; Antihistamine drugs; Cultures in vitro; Expression in PBMCs
• ISSN: 0171-2985; 1878-3279
• DOI: 10.1016/j.imbio.2016.11.004

Abstract Introduction Fexofenadine (FXF) is a third-generation antihistamine drug and osthole is assumed as a natural antihistamine alternative. This paper compares results of histamine, FXF and osthole impact on HRH-1, COX-2, NF-κB-p50, CCR1 mRNA expression. We also measured mRNA expression of IL-1β and CCL5/RANTES in incubated peripheral blood mononuclear cells (PBMC) to compared how histamine, FXF and osthole had influence on expression level and interacts on product secretion. Objective The purpose was to investigate expression pattern in asthma PBMC. Methods The cultures were treated 72 h with FXF and osthole. We measured mRNA expression of histamine HRH-1, COX-2, NF-κB-p50, CCR1, IL-1β and CCL5/RANTES with Real-Time PCR (RT-PCR). Results The present study suggest that osthole may be a potential inhibitor of histamine H1 receptor activity. We also demonstrated that cells cultured with histamine increase COX-2 mRNA expression and osthole reduce it. Conclusion Allergy remains one of the most common chronic diseases in Europe and it is rapidly approaching epidemic proportions; with current predictions estimating that the number of allergy-afflicted will equal the healthy population by 2020. It is therefore paramount to find new pharmaceuticals which successfully combat allergic disease.